Revance Therapeutics, Inc. $190 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “RVNC.”

Goldman Sachs & Co. LLC, Cowen, Barclays, Cantor, William Blair and SunTrust Robinson Humphrey acted as underwriters.

Based in Newark, California, Revance Therapeutics is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications.

The Davis Polk corporate team included partner Bruce K. Dallas (Picture) and associates Tyler P. Pender, Josephine Chen and Beth LeBow. The tax team included partner Rachel D. Kleinberg and associate Caroline E. Dayton. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang.

Involved fees earner: Bruce Dallas – Davis Polk & Wardwell; Tyler Pender – Davis Polk & Wardwell; Josephine Chen – Davis Polk & Wardwell; Beth LeBow – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Caroline Dayton – Davis Polk & Wardwell; Michelle Ontiveros Gross – Davis Polk & Wardwell; Jason Bang – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Barclays Bank; Goldman, Sachs & Co.; Cowen and Company; SunTrust Robinson Humphrey, Inc.; William Blair & Company, L.L.C.; Cantor Fitzgerald Securities;


Author: Ambrogio Visconti